LY75 and neoplasm: Direct in vivo DC vaccination involves the targeted delivery of tumor antigens to DCs through the use of chimeric proteins, which will fuse tumor antigens to antibodies specific for a given DC receptor, such as CD205 or Langerin/CD207 [72].